SequelSEC

FILANA THERAPEUTICS, INC. FLNA

Pharmaceutical Preparations · CIK 0001069530 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-03-31
Operating income
-$11.17M
Fiscal year ended 2026-03-31
Free cash flow
Unavailable
Fiscal year ended 2026-03-31

Valuation, from the filing

Public float$87.00MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.80Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / equity1.2×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Current ratio2.23x31th

FILANA THERAPEUTICS, INC. (FLNA) reported net income of -$10.33M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from FILANA THERAPEUTICS, INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

FILANA THERAPEUTICS, INC. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$11.17M-$13.55M-$11.86MUnavailableUnavailable-$29.49M-$30.62MUnavailableUnavailable-$22.79M
Net income-$10.33M-$12.54M-$10.81MUnavailableUnavailable-$27.60M-$27.94MUnavailableUnavailable-$20.92M
Research & development$4.54M$3.85M$3.96MUnavailableUnavailable$20.53M$17.68MUnavailableUnavailable$18.73M
Weighted-average diluted sharesUnavailableUnavailableshares 48.31MUnavailableUnavailableUnavailableshares 47.98MUnavailableUnavailableUnavailable
Pretax incomeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Income tax expense$0$0$0UnavailableUnavailable$0$0UnavailableUnavailableUnavailable
Diluted EPSUnavailableUnavailable$-0.22UnavailableUnavailableUnavailable$-0.58UnavailableUnavailableUnavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.62M$9.70M$7.90MUnavailableUnavailable$8.96M$12.95MUnavailableUnavailable$4.06M
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

FILANA THERAPEUTICS, INC. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Cash & equivalents$86.57M$95.50M$106.08MUnavailableUnavailable$128.57M$148.98MUnavailableUnavailable$121.14M
Total assets$108.37M$118.36M$129.73MUnavailableUnavailable$157.53M$223.75MUnavailableUnavailable$151.66M
Current assets$87.96M$97.71M$108.91MUnavailableUnavailable$136.53M$202.55MUnavailableUnavailable$129.63M
Total liabilities$40.23M$43.95M$48.16MUnavailableUnavailable$11.83M$57.11MUnavailableUnavailable$14.20M
Current liabilities$40.12M$43.83M$48.05MUnavailableUnavailable$11.75M$57.03MUnavailableUnavailable$14.20M
Total equity incl. NCI$68.14M$74.40M$81.57MUnavailableUnavailable$145.70M$166.64MUnavailableUnavailable$137.47M
Temporary (mezzanine) equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts payableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Cash flow

FILANA THERAPEUTICS, INC. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Operating cash flow-$8.88M-$9.75M-$6.22MUnavailableUnavailable-$61.26M-$18.30MUnavailableUnavailable-$22.32M
Capital expendituresUnavailable$501.00K$80.00KUnavailableUnavailable$57.00K$17.00KUnavailableUnavailable$41.00K
Investing cash flowUnavailable-$501.00K-$80.00KUnavailableUnavailable-$57.00K-$17.00KUnavailableUnavailable-$41.00K
Financing cash flow-$51.00K-$329.00K$0UnavailableUnavailable$918.00K$0UnavailableUnavailable$1.14M
Net change in cashUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Stock-based compensation$4.07M$5.37M$4.40MUnavailableUnavailable$5.74M$5.61MUnavailableUnavailable$2.13M
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

FILANA THERAPEUTICS, INC. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Free cash flowUnavailable-$10.25M-$6.30MUnavailableUnavailable-$61.32M-$18.31MUnavailableUnavailable-$22.36M
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.19x2.23x2.27xUnavailableUnavailable11.62x3.55xUnavailableUnavailable9.13x
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open FLNA in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-14View SEC filing
10-Q · Filed 2025-05-08View SEC filing
10-K · Filed 2025-03-03View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

14 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2025-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-06-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-06-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-03-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-03-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.